Pfizer Inc. PFE on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
Pfizer said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive ...
(NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy ...
The MarketWatch News Department was not involved in the creation of this content. -- VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher ...
Pfizer reaffirmed full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and full-year 2026 adjusted diluted earnings per share guidance of $2.80 to $3.00. Denton commented, "Our COVID ...
The announcement Monday from Pfizer and its German partner BioNTech that their coronavirus vaccine appears to be 90% effective thrilled medical experts around the world and presented a glimmer of hope ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results